The company will receive a milestone payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD)
Nordic Life Science
NLS News
The biotech company has announced the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from
After discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class
Malin Parkler, CEO of Pfizer Sweden, has been appointed new Chair of the Board of the Research-based Pharmaceutical Industry in Sweden (LIF). Parkler was elected to the Board of LIF
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
Labiotech.eu has chosen to highlight 20 women they think are making an impact in the European biotech industry, and among them is Carina Schmidt, the CEO of Athera Biotechnologies. Like
Drug & Device development
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease. Data
The company has completed patient enrollment in the phase Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable malignant pleural mesothelioma (MPM). The trial consists of a phase Ib
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful improvement in
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa. All participants have now been enrolled and the last travellers
The topline results from the 12-month follow-up review of the Phase 1 Lymfactin trial in breast cancer-associated lymphedema has been announced. The study’s data monitoring committee (DMC) concluded that the
The company will receive a milestone payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD)
Latest news
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease. Data
The company has completed patient enrollment in the phase Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable malignant pleural mesothelioma (MPM). The trial consists of a phase Ib
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful improvement in
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa. All participants have now been enrolled and the last travellers
The topline results from the 12-month follow-up review of the Phase 1 Lymfactin trial in breast cancer-associated lymphedema has been announced. The study’s data monitoring committee (DMC) concluded that the
The Permanent Secretary at Ministry of Health Dr Kennedy Malama together with the Swedish Ambassador Henrik Cederin, Dr Izukanji Sikazwe CEO at Centre for Infectious Disease Research in Zambia (CIDRZ)
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA
The latest research news from the Nordic region
Science Article
Scientists at Washington University School of Medicine and Umeå University have found a molecular compound that prevents and even reverses resistance to the most widely used antibiotic for treating tuberculosis
Radforsk, the Radium Hospital Research Foundation, is awarding several NOK 4.5 million to new research that fights cancer with light, reports Elisabeth Kirkeng Andersen, Oslo Cancer Cluster. Radforsk is an evergreen
We asked the new Minister about her goals and efforts when it comes to the country’s life science industry and Sweden’s status as an innovation and scientific research nation. How
The European Parliament has voted to end daylight saving time in EU member states. The biannual clock changes will come to an end in 2021 when individual member states will
A Karolinska Institutet study on mice shows that the antibodies stabilise the plaque that accumulates on the artery walls, which reduces the risk of it rupturing and causing a blood
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.